These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 32389886)

  • 1. Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis.
    Vilar-Gomez E; Calzadilla-Bertot L; Wong VW; Castellanos M; Aller-de la Fuente R; Eslam M; Wong GL; George J; Romero-Gomez M; Adams LA
    Clin Gastroenterol Hepatol; 2021 Jan; 19(1):136-145.e6. PubMed ID: 32389886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
    Vilar-Gomez E; Vuppalanchi R; Desai AP; Gawrieh S; Ghabril M; Saxena R; Cummings OW; Chalasani N
    Aliment Pharmacol Ther; 2019 Aug; 50(3):317-328. PubMed ID: 31157422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis.
    Kaplan DE; Serper M; John BV; Tessiatore KM; Lerer R; Mehta R; Fox R; Aytaman A; Baytarian M; Hunt K; Albrecht J; Taddei TH;
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2148-2160.e14. PubMed ID: 32798709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease.
    Yang JD; Ahmed F; Mara KC; Addissie BD; Allen AM; Gores GJ; Roberts LR
    Hepatology; 2020 Mar; 71(3):907-916. PubMed ID: 31309602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis B After Decompensation With Ascites.
    Tan HK; Teng MLP; Soh AYS; Cheo SHY; Fook-Chong S; Goh GBB; Tan CK; Wong GW; Lee GH; Chang JPE
    Am J Gastroenterol; 2021 Jul; 116(7):1437-1446. PubMed ID: 33834737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis.
    Yen FS; Huang YH; Hou MC; Hwu CM; Lo YR; Shin SJ; Hsu CC
    Br J Clin Pharmacol; 2022 Jan; 88(1):311-322. PubMed ID: 34198358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The survival outcomes and prognostic factors of hepatocellular carcinoma among type 2 diabetes patients: a two-centre retrospective cohort study.
    Azit NA; Sahran S; Meng LV; Subramaniam MK; Mokhtar S; Nawi AM
    Turk J Med Sci; 2022 Oct; 52(5):1580-1590. PubMed ID: 36422484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis.
    Huang DQ; Noureddin N; Ajmera V; Amangurbanova M; Bettencourt R; Truong E; Gidener T; Siddiqi H; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Yoneda M; Nakajima A; Idilman R; Gumussoy M; Oz DK; Erden A; Allen AM; Noureddin M; Loomba R
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):829-836. PubMed ID: 37419133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis.
    Huynh DJ; Renelus BD; Jamorabo DS
    BMC Gastroenterol; 2023 Dec; 23(1):450. PubMed ID: 38114915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.
    Aminian A; Al-Kurd A; Wilson R; Bena J; Fayazzadeh H; Singh T; Albaugh VL; Shariff FU; Rodriguez NA; Jin J; Brethauer SA; Dasarathy S; Alkhouri N; Schauer PR; McCullough AJ; Nissen SE
    JAMA; 2021 Nov; 326(20):2031-2042. PubMed ID: 34762106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease.
    Petta S; Sebastiani G; Viganò M; Ampuero J; Wai-Sun Wong V; Boursier J; Berzigotti A; Bugianesi E; Fracanzani AL; Cammà C; Enea M; Grottes MD; Di Marco V; Younes R; Keyrouz A; Mazzola S; Mendoza Y; Pennisi G; Romero-Gomez M; Craxì A; de Ledinghen V
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):806-815.e5. PubMed ID: 32621970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of Race and Ethnicity with Hepatocellular Carcinoma, Decompensation, and Mortality in US Veterans with Cirrhosis.
    VoPham T; Cravero A; Feld LD; Green P; Feng Z; Berry K; Kim NJ; Vutien P; Mendoza JA; Ioannou GN
    Cancer Epidemiol Biomarkers Prev; 2023 Aug; 32(8):1069-1078. PubMed ID: 37255388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis.
    Vilar-Gomez E; Vuppalanchi R; Gawrieh S; Ghabril M; Saxena R; Cummings OW; Chalasani N
    Hepatology; 2020 Feb; 71(2):495-509. PubMed ID: 30506586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.
    Stine JG; Wentworth BJ; Zimmet A; Rinella ME; Loomba R; Caldwell SH; Argo CK
    Aliment Pharmacol Ther; 2018 Oct; 48(7):696-703. PubMed ID: 30136293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
    Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
    BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Diabetes and Glucose-Lowering Therapies on Hepatocellular Carcinoma Incidence and Overall Survival.
    Hydes TJ; Cuthbertson DJ; Graef S; Berhane S; Teng M; Skowronska A; Singh P; Dhanaraj S; Tahrani A; Johnson PJ
    Clin Ther; 2022 Feb; 44(2):257-268. PubMed ID: 35078642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in Characteristics, Mortality, and Other Outcomes of Patients With Newly Diagnosed Cirrhosis.
    Orman ES; Roberts A; Ghabril M; Nephew L; Desai AP; Patidar K; Chalasani N
    JAMA Netw Open; 2019 Jun; 2(6):e196412. PubMed ID: 31251379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.